Abstract:Voltage-gated Na+ (Nav) channels provide the basis for neuronal excitability in the brain. Of the nine Nav channel isoforms (Nav1.1-Nav1.9), Nav1.1 exhibits cell-specific distribution in fast-spiking parvalbumin (PV) interneurons in the cortical circuit. Reduced function of PV interneurons results in impairment of the cognitive domain, a bio-signature common to a variety of neuropsychiatric disorders. Thus, selective allosteric modulators targeting Nav1.1 might provide new means to rescue PV interneuron function and improve cognition. Previous studies have identified fibroblast growth factor 14 (FGF14) as a functionally relevant regulator of Nav1.1 channels. Binding of FGF14 to the Nav1.1 C-terminal tail results in modulation of Nav1.1-mediated peak transient currents and biophysical properties of the channel activation and steady-state inactivation. The FGF14:Nav1.1 protein:protein interaction (PPI) interface might therefore provide a novel target for the development of Nav1.1 allosteric modulators. In search of small molecules targeting Nav1.1, we conducted a ligand-based high-throughput virtual screening using a FGF14:Nav1.1 homology model based on available crystal structures of homologous proteins. The UCSF chimera software was used to determine the region of interaction between FGF14 and Nav1.1, and Autodock was used to create a grid box surrounding this area to identify critical amino acids at the PPI surface of FGF14.This region of interest was submitted to the Texas Advanced Computing Center (TACC) drug discovery database, which identified 1001 ZINC compounds out of 642,759 possible ligands against the interaction site. Scores ranged from −13 to 0, with lower scores indicating greater likelihood of binding to the FGF14 surface, and thus interfering with Nav 1.1 binding. On-going counter and orthogonal screenings using in heterologous systems as well as Schrödinger Advanced Drug Discovery Suite are being used to provide in-cell validation of 14 identified hits and understanding of the target-ligand interactions. These small molecules might represent a new class of PPI-based Nav1.1-specific allosteric modulators with applicability as cognitive enhancers.

Mechanism-specific Assay Design Facilitates the Discovery of Nav1.7-selective Inhibitors

Identification of Small-Molecule Ion Channel Modulators in C. Elegans Channelopathy Models.

Targeting Protein: Protein Interaction Sites for Drug Development Against Voltage-Gated Sodium Channels

Development of a Rapid Throughput Assay for Identification of hNav1.7 Antagonist Using Unique Efficacious Sodium Channel Agonist, Antillatoxin

Virtual Screening in Search of Allosteric Modulators of Nav1.1 Channels

Cryo-EM reveals an unprecedented binding site for NaV1.7 inhibitors enabling rational design of potent hybrid inhibitors

Evaluating State Dependence and Subtype Selectivity of Calcium Channel Modulators in Automated Electrophysiology Assays

Prediction and Optimization of NaV1.7 Sodium Channel Inhibitors Based on Machine Learning and Simulated Annealing.

Identification of Peptidomimetics As Novel Chemical Probes Modulating Fibroblast Growth Factor 14 (FGF14) and Voltage-Gated Sodium Channel 1.6 (nav1.6) Protein-Protein Interactions

Drug discovery targeting Nav1.8: Structural insights and therapeutic potential

Structural Insights into the Atomistic Mechanisms of Action of Small Molecule Inhibitors Targeting the KCa3.1 Channel Pore

Use-Dependent Relief of Inhibition of Nav1.8 Channels by A-887826

High-throughput Electrophysiological Assays for Voltage Gated Ion Channels Using SyncroPatch 768PE.

Unique electrophysiological property of a novel Nav1.7, Nav1.8, and Nav1.9 sodium channel blocker, ANP-230

Application of an in Vitro Model for Early Detection of Cardiac Sodium Channel Blocking Liabilities

Naphthylisoquinoline alkaloids, a new structural template inhibitor of Nav1.7 sodium channel

Structural basis for modulation of human Na V 1.3 by clinical drug and selective antagonist

Selective Voltage-Gated Sodium Channel Peptide Toxins from Animal Venom: Pharmacological Probes and Analgesic Drug Development

Structure-based discovery of potassium channel blockers from natural products: virtual screening and electrophysiological assay testing.

Design, Synthesis, And Pharmacological Evaluation Of Analogues Derived From The Plev Tetrapeptide As Protein-Protein Interaction Modulators Of Voltage-Gated Sodium Channel 1.6

Optimising experimental designs for model selection of ion channel drug binding mechanisms